Development and validation of an
HPLC method to analyze ibuprofen and
impurities according to the European

This Application Note describes the development of a fast, accurate, and reproducible method to analyze ibuprofen and related impurities according to European Pharmacopoeia (EP) regulations1, using an Agilent 1120 Compact LC. The experiments described in this Application Note include determination of precision of areas and reten- tion times, as well as chromatographic parameters like resolution and signal-to-noise ratios. The experiments prove precise results from a system that was optimized for everyday productivity, and they fulfill Introduction
Step 1 – Preparation of individual Step 2 – Preparation of solution Step 3 – Preparation of reference tion from step 2 was added andthe mixture was diluted to 10 mL (6 µg/mL) of each of the impurities.
Chromatographic conditions
System suitability and performance
Preparation of samples
Solvents, gradient, and pump settings
main peak must be linear with-out dilution.
Number of injections
Verify baseline stability and identify artifacts Verify stability of response and correctness of Results and discussion
Table 1
Setup for testing system suitability and performance.

Retention time (min)
ria were fulfilled. The requiredsensitivity was obtained for all Table 2
Results for control sample: resolution and signal-to-noise (S/N) ratio.

peaks and resolution > 1.5 wasachieved for all compounds in the Compound
Retention time (min)
Suitability sample: precision of retention times and areas. (RSD = relative standard deviation; RT
= retention time).

was proven. For all components,the criteria for precision of reten- Residual r
standard deviation

tion times and areas were fulfilled,showing that the system can be Calibration (Setting “Ignore Origin”, y=mx+b, 0.6 to 9 µg/mL for impurities and 0.2 to 3 mg/L for

the concentration of the referencesolution) to the highest concentra- References
correlation results (r>0.999) dur-ing calibration, which is also proof European Pharmacopoeia 4.2,
Council of Europe, 2737-9,
Specifications, Ordering,” Agilent 5989-7454ENA, 2008.
use, as well as the lowest cost-of-ownership for standard LC Substances, Revision 2,http://www.fda.gov/cder/guid- ance/7838fnl.pdf, 2008.
from a system that was optimizedfor everyday productivity, and to number 5989-5621EN, 2006.
results show that the instrument iswithin the limits of the regulatoryrequirements for a quality controlenvironment.
The results show explicitly theapplicability of the 1120 LC sys-tem for pharmaceutical testing in QA/QC departments. In additionto the instrument capabilities, the new version of the Agilent wide range of features for dataanalysis and reporting of theresults.
Published June 15, 2010Publication Number 5989-9241EN

Source: http://anatox.de/Datenblaetter_Publikationen/5989-9241EN.pdf

Sedation instructions

www.kidsandteensdentistry.com INFORMATION FOR PARENTS OF CHILDREN BEING TREATED WITH CONSCIOUS SEDATION Conscious sedation is used to help children who are unable to accept dental treatment in the usual manner due to their young age, fear, or large amount of treatment that is required. Conscious sedation is NOT the same as general anesthesia and your child will not be asleep as fo

Microsoft word - 12-13 rx communication rev2.doc

McKesson 12/13/11 Rx Availability Update INJECTABLE FENTANYL STATUS Situation: All manufactures are on backorder. 1) Hospira production delays due plant issues/upgrades; 2) Westward acquired Baxter’s Fentanyl products, delaying production. Below are the items, listed by Supplier, that are expected to be the 1st to recover. Check these for availability frequently: Hospira ite

Copyright © 2010-2014 Internet pdf articles